The adage “time is money” is as pertinent to clinical research as to any other corner of the business world. The longer a study drags on, the bigger its price tag becomes. Study timelines can be a source of much anxiety for researchers, creating the markets for time-saving innovations like EDC, eSource, and risk-based monitoring. Recent trends are not easing this anxiety: a study by Cutting Edge Information finds that early-phase clinical trial budgets increased 157% between 2008 and 2013, with the biggest spike, of $23,600 per patient, occurring in Phase I. Now, several years removed from this time frame, there is evidence these trends are continuing. The study cites a shift toward more complex study protocols in Phase I, a trend still relevant today; as we discussed last month, Bracken Data recently noted an uptick in Phase I patient enrollment, which impacts overall trial cost.